← Back to patent-cliff list
Cevimeline Hydrochloride Hydrate
Tier C — Watch / tradeCevimeline Hydrochloride Hydrate
Daiichi Sankyo Co., Ltd.
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CHRM1, CHRM3
Brand：Evoxac, Saligren
Indications (approved)：Sjögren's syndrome
Regional status
US
Approved
2000-01-11
EU
-
China
Discontinued
2011-08-02
Japan
Approved
2001-06-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cevimeline Hydrochloride Hydrate?
Approved indications include: Sjögren's syndrome.
When does the Cevimeline Hydrochloride Hydrate patent expire?
No public expiry year is available for Cevimeline Hydrochloride Hydrate yet; this page updates once verified.
How do I get a quote for Cevimeline Hydrochloride Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27